IPP Bureau
Contineum MS drug stumbles in mid-stage trial
By IPP Bureau - November 24, 2025
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
BioNxt secures Eurasian patent for breakthrough sublingual MS therapy
By IPP Bureau - November 24, 2025
The Eurasian Patent Organization (EAPO) has granted Patent, protecting the company’s sublingual delivery technology for anticancer drugs used to treat autoimmune and neurodegenerative diseases
Dr Reddy’s receives EU nod for AVT03 biosimilar denosumab
By IPP Bureau - November 24, 2025
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
Hester Biosciences appoints Ashish Desai as CFO
By IPP Bureau - November 23, 2025
Desai is currently serving the company as Group Finance Controller
Aayush Wellness partners with Blinkit to strengthen distribution network
By IPP Bureau - November 23, 2025
The partnership will enable rapid and reliable product delivery
Cosmo and Glenmark receives market authorization of Winlevi in Europe
By IPP Bureau - November 23, 2025
Winlevi is authorized in EU for the treatment of acne vulgaris
Solara’s Mangalore facility clears FDA inspection with VAI status
By IPP Bureau - November 23, 2025
Biocon Pharma gets FDA nod for arthritis drug Tofacitinib ER
By IPP Bureau - November 23, 2025
Tofacitinib extended-release tablets are a Janus kinase inhibitor indicated for Rheumatoid Arthritis
Croda partners with Amino to expand biopharma capabilities
By IPP Bureau - November 23, 2025
The partnership combines Croda’s deep expertise in smart science and global market reach with Amino’s advanced capabilities in precision manufacturing of amino acids
ACG unveils patent-clean laminate ‘DryPod’ to shake up moisture-protection market
By IPP Bureau - November 23, 2025
The company says the innovation delivers stronger moisture protection for highly sensitive drug molecules
Neurocrine review highlights key differences between tardive dyskinesia drugs
By IPP Bureau - November 23, 2025
Rafa Laboratories lands $186 million BARDA contract to develop life-saving trauma drug
By IPP Bureau - November 23, 2025
Landmark studies have shown that rapid TXA administration can significantly reduce mortality
FDA approves combo therapy for Cisplatin-ineligible muscle-invasive bladder cancer patients
By IPP Bureau - November 23, 2025
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
AstraZeneca to invest $2 billion in Maryland manufacturing expansion
By IPP Bureau - November 22, 2025
The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan
Roche wins EU green light for one-minute injection cancer therapy
By IPP Bureau - November 22, 2025
